Brind.

Arvinas was classified in the Zacks Medical - Biomedical and Genetics industry and underperformed the S&P 500 this year.

1 report, 1 independent Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Arvinas was classified in the Zacks Medical - Biomedical and Genetics industry and underperformed the S&P 500 this year.

Who's involved

What this event is mainly about
Arvinas (United States)

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksArvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This comp